Sources used: dp news agency
The corona crisis is a paradigm shift: "It inspires acceptance of the purchase of pharmaceuticals by mail." The entrepreneur expects that the sales of prescription drugs in Germany at mail-order pharmacies through the e-prescription will rise from 1.4 percent today to more than five percent in three to five years. Its target group are chronically ill people who regularly take medication.
As a platform operator, the Zur Rose Group would also earn from sales of non-prescription drugs from others who offer services there – like Amazon on its own platform. According to the industry, the company collects 15 percent. Oberhänsli does not say what Zur Rose is planning. Just this: "We are not based on Amazon". There may also be special prices in the introductory phase.
Scientists around the world are researching a vaccine against the coronavirus. Only tests can show whether and how individual vaccine candidates work. Now a US company gives cause for hope.
The biotech company Moderna has presented interim results of the tests of a corona vaccine candidate in relation to the elderly to the US health authority CDC. The results are "very positive and agree with the results of younger subjects", said the press office of the US company.
The vaccine mRNA-1273 elicited a similarly good immune response as in younger people, and there were no serious side effects.
Phase III clinical study with 30,000 subjects
Moderna announced in July that it had started a phase III clinical study with 30,000 subjects with the vaccine candidate. A phase III study will examine whether and how well a vaccine actually protects against infection.
First approved corona vaccination: How safe is the vaccine from Russia? Four phases briefly explained: Corona vaccine – why does it take so long? Immunity from previous infections: do colds protect against Covid-19?
The study is taking place at 89 locations in the United States, it said. According to the World Health Organization (WHO), only a handful of other active ingredients are currently being researched at a similarly advanced stage.
Sources used: dpa news agency–>
Therefore, if valuable time is lost in treatment, women are at greater risk of dying from heart attack or of having permanent damage.
Overall, more women than men die of cardiovascular diseases if, in addition to heart attacks, cardiac insufficiency, cardiac arrhythmias and damage to the heart valves are also included. This emerges from the 2013 Heart Report of the German Heart Foundation.
The professor from Vienna says: "Most risk factors affect women more dramatically than men". This applies to smoking, increased blood lipid levels, high blood pressure, obesity and lack of exercise.
Risk factors for women’s hearts
In addition, there are gender-specific, often hormone-related risk factors for women’s hearts:
irregular cycle pregnancy diabetes long-term use of the pill hormone replacement therapy high blood pressure after menopause unfavorable changes in body fat distribution after menopause
Blood lipid lowering agents for men and women
The experts in gender medicine are also finding more and more evidence that drugs work differently in men’s and women’s bodies. Kautzky-Willer describes this using the example of cholesterol-lowering drugs. They are prescribed to prevent a heart attack caused by blocked blood vessels. So far, statins have been the standard medication. They block the formation of the "bad" LDL cholesterol.
According to Kautzky-Willer, statins work less well in women than in men. Now doctors are relying on a new type of cholesterol-lowering drug, so-called PCSK9 inhibitors. They accelerate the breakdown of LDL cholesterol in the blood. One disadvantage is that they have to be injected under the skin.
More deaths than men: Heart attacks are often detected too late in women Diabetes and other risk factors: Heart attack: When women are particularly at risk Broken Heart Syndrome: Hearts can also break due to happiness Broken Heart Syndrome: Broken heart syndrome affects Women more often
Berlin (dpa) – In Germany, fluoroquinolones are still often prescribed: a group of antibiotics that can have serious side effects.
Member of the Bundestag expects sexist attacks
Trump casino is blown up – who can push the button?
Influencer (30) dies in butt lift
Elephant cow gives birth – reaction of the herd amazes
US Vice President Pence vaccinated against Corona
NASA mission enables a first look inside Mars
These rules apply to your fireworks in the garden
Spahn asks for patience when distributing the vaccine
Strange beer appearance in the US Parliament
Suddenly there is no stopping the minister
Container use due to Corona causes a stir
Towing service has a bad surprise
Winter weather causes chaos on the US east coast
What are the chances of a white Christmas?
Santa Claus approaches with a sledgehammer
In the US, the consequences of side effects are considered to be "Fluoroquinolone-Associated Disability" (FQAD, roughly: damage associated with fluoroquinolone) and are recognized as a disease. Pieper is currently working on the development of diagnostic criteria for FQAD and has written the first German-language specialist article on the subject. "Through this work, I have identified at least 200 symptoms that can occur with FAQD"he sums up.
According to Pieper, the side effects can be divided into four groups. For one thing, fluoroquinolones attack the collagen in the body, which can lead to torn tendons, retinal detachments, and torn arteries. Second, these antibiotics have a neurotoxic effect, which could cause long-term, sometimes difficult-to-treat nerve damage. A third possible side effect concerns neurotransmitters whose receptors could be blocked by fluoroquinolones. Patients would then become restless, anxious or panicked and could even develop suicidal tendencies. And finally, chronic fatigue syndrome is possible – a particularly difficult fate for Pieper, who has already seen a large number of side effects in his practice: "Those affected lose their jobs, experience social decline and family breakdown and, most importantly, they are least believed."
For Wolfgang Becker-Brüser from the trade journal "Remedy telegram" In view of the possible long-lasting side effects, it is incomprehensible that fluoroquinolones are still being prescribed for common infections. "These are absolute reserves that should only be used if nothing else helps"said the doctor and pharmacist. In fact, the Federal Institute for Drugs and Medical Devices (BfArM) published a so-called in April of this year "Red hand letter", which said that doctors should only prescribe fluoroquinolones on a case-by-case basis because of severe side effects. Previously, the office had launched a European risk assessment process in 2017.
These measures come too late for Becker-Brüser: "There has been criticism of the funds since the market launch in the 80s." In addition, the Federal Health Office at that time recommended strict indications for the prescription of fluoroquinolones as early as 1989, although these were not mandatory. He therefore perceives the projections in the WIdO report as "Bankruptcy of drug surveillance", even if estimates should of course be treated with caution. Nevertheless, 11 of the 16 fluoroquinolone representatives that were once available in Germany were withdrawn from the market, some of them shortly after their introduction: "That shows the damage potential."
The WIdO report also criticizes the fact that the BfArM reacted too late to the known risks. Upon request, the authority will respond in writing: "The BfArM has not only dealt with risks in connection with the use of fluoroquinolones since the risk assessment procedure was triggered in 2017, but was and is continuously involved in the monitoring and evaluation of the safety of fluoroquinolone-containing drugs at European level."
The Federal Institute refers to several Rote-Hand letters and publications on the subject, but also to the responsibility of doctors and patients: "For the safe use of a drug, it is crucial that users – doctors and patients alike – use the product information texts to find out about the risks of use and that patients contact their doctor if they have any questions." In addition, fluoroquinolones are approved in almost all European countries, measures to change the approval conditions would have to be coordinated at European level.
Wolfgang Becker-Brüser demands that the areas of application should be clearly positioned as early as possible when drugs are approved. If relevant restrictions were found after approval, clear warnings, such as those in the USA as "boxed warning" come first in the product information, helpful. He sees specific information in the practice software of doctors, as advocated by the WIdO report, as the last possible step – similar to Pieper. The corresponding programs are not yet good enough.
Superfood: The 15 Healthiest Foods
Photo series with 15 pictures